Sec Form 4 Filing - De Paolantonio Ernest Robert @ BIODELIVERY SCIENCES INTERNATIONAL INC - 2018-04-03

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person De Paolantonio Ernest Robert 2. Issuer Name and Ticker or Trading Symbol BIODELIVERY SCIENCES INTERNATIONAL INC [ BDSI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CFO, Secretary and Treasurer (Last) (First) (Middle) C/O BIODELIVERY SCIENCES INTL, INC.,, 4131 PARKLAKE AVE. SUITE 225 3. Date of Earliest Transaction (MM/DD/YY) 04/03/2018 (Street) RALEIGH, NC27612 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/03/2018 A 1,267 A $ 0 ( 1 ) 97,731 D Common Stock 04/03/2018 M( 2 ) 34,391 A $ 0 ( 2 ) 132,122 D Common Stock 04/03/2018 M( 3 ) 30,000 A $ 0 ( 3 ) 162,122 D Common Stock 04/03/2018 M( 4 ) 31,667 A $ 0 ( 4 ) 193,789 D Common Stock 04/03/2018 M( 5 ) 27,075 A $ 0 ( 5 ) 220,864 D Common Stock 04/05/2018 S( 6 ) 30,900 D $ 2.12 ( 7 ) 189,864 D Common Stock 04/06/2018 S( 6 ) 33,255 D $ 2.06 ( 8 ) 156,709 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units $ 0 04/03/2018 A( 1 ) 1,267 ( 1 ) 04/03/2018 Common Stock 1,267 $ 0 0 D Restricted Stock Units $ 0 04/03/2018 M( 2 ) 34,391 ( 2 ) 04/03/2018 Common Stock 34,391 $ 0 0 D Restricted Stock Units $ 0 04/03/2018 M( 3 ) 30,000 ( 3 ) 03/01/2019 Common Stock 30,000 $ 0 30,000 D Restricted Stock Units $ 0 04/03/2018 M( 4 ) 31,667 ( 4 ) 02/06/2020 Common Stock 31,667 $ 0 63,333 D Restricted Stock Units $ 0 04/03/2018 A( 5 ) 27,075 ( 5 ) 02/06/2020 Common Stock 27,075 $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other De Paolantonio Ernest Robert C/O BIODELIVERY SCIENCES INTL, INC., 4131 PARKLAKE AVE. SUITE 225 RALEIGH, NC27612 CFO, Secretary and Treasurer Signatures /s/ Ernest R. De Paolantonio 04/06/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. ( 2 )The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. ( 3 )The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019. ( 4 )The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. ( 5 )The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. ( 6 )The shares of common stock were sold by the Reporting Person upon expiration of a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's additional tax liability upon the vesting of the Reporting Person's RSUs. ( 7 )On April 5, 2018, the Reporting Person sold an aggregate of 30,900 shares of the Issuer's Common Stock at a weighted average price of $2.12 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.08 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 8 )On April 6, 2018, the Reporting Person sold an aggregate of 33,255 shares of the Issuer's Common Stock at a weighted average price of $2.06 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.